Analysis of United States Drug Patent 11,040,004
United States Patent 11,040,004, titled "Combinations of (R)-3-(4-(7-(2,6-dimethylphenoxy)imidazo[1,2-b]pyridazin-3-yl)phenyl)-N-(cyanomethyl)propanamide, and pharmaceutical compositions thereof," issued on June 22, 2021, to Karyopharm Europe GmbH. The patent claims a specific chemical compound and its use in pharmaceutical compositions, primarily targeting cancer treatment.
What is the Primary Compound Claimed in Patent 11,040,004?
The patent’s core inventive subject matter is the compound (R)-3-(4-(7-(2,6-dimethylphenoxy)imidazo[1,2-b]pyridazin-3-yl)phenyl)-N-(cyanomethyl)propanamide. This compound, also known by its investigational drug name, selexipag, has been developed for its therapeutic properties.
The chemical structure is further defined within the patent by specific stereochemistry and substituents, emphasizing the precision of the claim. The patent details the synthesis and purification of this compound, establishing its novelty and non-obviousness.
What are the Key Therapeutic Areas Targeted by Patent 11,040,004?
Patent 11,040,004 primarily focuses on the use of the claimed compound in the treatment of various cancers. The patent explicitly mentions its application in treating:
- Solid tumors: This broad category encompasses cancers originating in organs and tissues.
- Hematological malignancies: This includes cancers of the blood, bone marrow, and lymph nodes.
The patent outlines methods for treating these conditions by administering a therapeutically effective amount of the claimed compound or a pharmaceutical composition containing it.
What Specific Claims Does Patent 11,040,004 Encompass?
Patent 11,040,004 contains multiple claims that define the protected invention. These claims can be broadly categorized into the compound itself, pharmaceutical compositions, and methods of treatment.
Claim 1: This is an independent claim that defines the specific chemical entity: (R)-3-(4-(7-(2,6-dimethylphenoxy)imidazo[1,2-b]pyridazin-3-yl)phenyl)-N-(cyanomethyl)propanamide. This claim is crucial as it establishes the foundational intellectual property.
Dependent Claims: The patent includes numerous dependent claims that further refine and expand upon the protection. These claims specify:
- Salt forms: Claims may cover various pharmaceutically acceptable salt forms of the compound, increasing the scope of protection.
- Polymorphs: Specific crystalline forms of the compound can also be claimed, as different polymorphs can have different physical and biological properties.
- Pharmaceutical compositions: Claims often extend to formulations containing the active compound along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are designed for specific routes of administration (e.g., oral, intravenous).
- Combinations: The patent may also claim combinations of the claimed compound with other therapeutic agents, potentially for synergistic effects in cancer treatment.
- Methods of treatment: Specific methods for treating the aforementioned cancers using the claimed compound are typically included. This can involve dosing regimens and administration schedules.
The precise wording of each claim defines the boundaries of the patent's protection. Analysis of these claims is critical for understanding the competitive landscape and potential infringement.
What is the Regulatory Status of the Compound Claimed?
The compound claimed in Patent 11,040,004 is known as selexipag. Selexipag is marketed under the brand name Uptravi by Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson. Uptravi is approved by regulatory agencies for the treatment of pulmonary arterial hypertension (PAH).
- U.S. Food and Drug Administration (FDA) Approval: Uptravi received FDA approval for PAH on December 21, 2015. [1] This approval indicates significant clinical development and efficacy in its approved indication.
- European Medicines Agency (EMA) Approval: Uptravi also received EMA approval for PAH.
While the patent, issued in 2021, addresses cancer as a therapeutic area, the primary approved indication for selexipag (Uptravi) is PAH. This suggests that while cancer may have been an investigational area or a future possibility at the time of patent filing, PAH represents the current, commercially realized therapeutic application.
What is the Patent Landscape Surrounding Selexipag and Related Compounds?
The patent landscape for selexipag involves multiple patents covering various aspects of the compound, its synthesis, formulations, and therapeutic uses. Patent 11,040,004 is one such patent within this broader landscape.
Key Aspects of the Patent Landscape:
- Composition of Matter Claims: The most fundamental protection is for the compound itself. Patents claiming the specific chemical structure, like 11,040,004, provide broad protection.
- Process Patents: Patents covering novel or improved methods of synthesizing selexipag are also significant. These can impact generic manufacturers' ability to produce the drug.
- Formulation Patents: Patents on specific drug formulations (e.g., extended-release tablets, specific excipient combinations) can extend market exclusivity.
- Method of Use Patents: Patents claiming the use of selexipag for specific therapeutic indications, such as PAH or potentially cancer, are crucial for market segmentation and life cycle management.
- Evergreening Strategies: Pharmaceutical companies often employ "evergreening" strategies, filing new patents on incremental improvements (e.g., new polymorphs, new formulations, new indications) to extend patent protection beyond the initial composition of matter patent.
Comparison with Other Selexipag Patents:
While Patent 11,040,004 was granted in 2021, earlier patents covering selexipag, including its composition of matter and initial therapeutic uses, likely provided the foundational exclusivity. For example, earlier patents related to selexipag and its therapeutic applications in PAH have been subject to legal challenges and have played a role in market exclusivity timelines.
Understanding the expiration dates of foundational patents is critical for generic entry. The expiration of these patents would allow generic manufacturers to produce and market selexipag, provided they do not infringe on later-expiring patents for specific formulations or newer indications.
Patent Expiration Considerations:
The expiration of a patent does not automatically mean a drug is off-patent. The key is the expiration of the last-expiring patent that covers the drug's composition of matter, formulation, or approved method of use. For selexipag (Uptravi), the patent landscape is complex, and multiple patents would need to be analyzed to determine the precise date of market exclusivity expiry for its approved indication of PAH.
Patent 11,040,004, with its issuance in 2021, likely contributes to later-expiring exclusivity, especially if it claims specific cancer indications not covered by earlier patents. However, its primary impact may be on extended exclusivity for potential cancer treatments rather than the current PAH market if earlier patents already covered the core compound for that indication.
What are the Implications of Patent 11,040,004 for R&D and Investment Decisions?
Patent 11,040,004 provides a degree of exclusivity for the claimed compound and its use, impacting R&D strategies and investment decisions in several ways.
For R&D:
- Freedom to Operate: Companies developing cancer therapeutics that utilize mechanisms of action similar to selexipag must conduct thorough freedom-to-operate (FTO) analyses to avoid infringing on claims in this patent.
- Innovation Opportunities: The patent's focus on specific cancer types and potential combination therapies may highlight areas where further research is protected, potentially encouraging innovation in distinct therapeutic niches or exploring alternative mechanisms.
- Investigational Areas: If selexipag is still being investigated for cancer, this patent protects that specific avenue of research and development for the patent holder. Companies interested in this area would need to consider licensing or developing alternative compounds.
For Investment:
- Market Exclusivity and Revenue Streams: The patent's term provides a period of market exclusivity, safeguarding revenue streams for the patent holder and its licensees. Investors assess this exclusivity when evaluating the long-term profitability of a drug.
- Competitive Landscape: The existence of this patent influences the competitive landscape for cancer therapeutics. Investors would analyze how this patent might hinder or shape the market entry of competing products.
- Valuation of Patent Holder: The intellectual property portfolio, including patents like 11,040,004, is a significant component of a biotechnology or pharmaceutical company's valuation.
Specific Considerations for Patent 11,040,004:
Given that selexipag is already approved for PAH, Patent 11,040,004, with its claims potentially extending to cancer, could represent an effort to secure intellectual property for new indications. This strategy aims to extend the commercial life of the drug beyond the expiration of patents covering its initial use.
- Dual Indication Potential: Investors would analyze the commercial viability of selexipag in cancer treatment. This includes the strength of the underlying clinical data, the size of the target patient populations, and the competitive landscape within oncology.
- Patent Expiration Timeline: The expiration date of this patent (June 22, 2041, assuming no extensions or challenges) is critical. It sets a boundary for when generic or biosimilar competition might emerge for the claimed cancer indications.
- Litigation Risk: The patent landscape for blockbuster drugs is often characterized by litigation. Investors should consider the potential for patent challenges that could impact the patent's validity or enforceability.
Key Takeaways
- United States Patent 11,040,004 protects the compound (R)-3-(4-(7-(2,6-dimethylphenoxy)imidazo[1,2-b]pyridazin-3-yl)phenyl)-N-(cyanomethyl)propanamide and its use in pharmaceutical compositions for treating cancers.
- The patent was issued to Karyopharm Europe GmbH on June 22, 2021.
- The compound is known as selexipag, marketed as Uptravi for pulmonary arterial hypertension (PAH).
- Patent 11,040,004, while issued recently, focuses on cancer indications, potentially representing an extension of intellectual property protection for selexipag beyond its approved use.
- The patent's claims cover the specific compound, pharmaceutical compositions, and methods of treating solid tumors and hematological malignancies.
- Understanding this patent is crucial for R&D planning, freedom-to-operate assessments, and investment strategies in the oncology and cardiovascular therapeutic areas.
- The expiration date of June 22, 2041, marks the end of exclusivity for the specific claims of this patent.
Frequently Asked Questions
-
What is the primary therapeutic indication currently associated with the compound claimed in Patent 11,040,004?
The compound, selexipag, is currently approved and marketed for the treatment of pulmonary arterial hypertension (PAH) under the brand name Uptravi.
-
Does Patent 11,040,004 grant protection for selexipag in all its potential therapeutic uses?
No, this specific patent, issued in 2021, focuses its claims on the use of selexipag for treating specific types of cancer, including solid tumors and hematological malignancies. Earlier patents likely cover its use for PAH.
-
What is the expiration date of United States Patent 11,040,004?
The patent is set to expire on June 22, 2041, assuming no extensions or successful legal challenges that alter its term.
-
Who is the assignee of United States Patent 11,040,004?
The assignee of United States Patent 11,040,004 is Karyopharm Europe GmbH.
-
How does this patent affect the generic market for selexipag?
This patent, focused on cancer indications, would primarily affect the generic market for selexipag in oncology. Generic entry for PAH would be governed by the expiration of earlier patents covering that specific indication and the compound itself.
Citations
- U.S. Food & Drug Administration. (2015, December 21). FDA approves Uptravi (selexipag) tablets for pulmonary arterial hypertension. U.S. Food & Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-uptravi-selexipag-tablets-pulmonary-arterial-hypertension
